A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. (Q47804487)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Silvia Sandini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

8

Antonio Cassone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Flavia De Bernardis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Mario Amacker

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Christel Gremion

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Rinaldo Zurbriggen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Christian Moser

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

English

0 references

publication date

3 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

4490-4498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22561143%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

cites work

Emerging fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Epidemiology of invasive candidiasis: a persistent public health problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

7 January 2021

Vulvovaginal candidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Immunopathogenesis of recurrent vulvovaginal candidiasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Innate immune mechanisms for recognition and uptake of Candida species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Candida albicans secreted aspartyl proteinases in virulence and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

The secreted aspartic proteinases as a new target in the therapy of candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Evidence for a correlation between proteinase secretion and vulvovaginal candidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Influenza virosomes as a vaccine adjuvant and carrier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Epaxal: a virosomal vaccine to prevent hepatitis A infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Differential expression of Candida albicans secreted aspartyl proteinase and phospholipase B genes in humans correlates with active oral and vaginal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Fungal vaccines: real progress from real challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Advances in combating fungal diseases: vaccines on the threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Prospects for development of vaccines against fungal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

A novel glyco-conjugate vaccine against fungal pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Prospects for development of a vaccine to prevent and control vaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

Candida albicans proteinases and host/pathogen interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

The yeast Candida albicans evades human complement attack by secretion of aspartic proteases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069

The Inflammatory response induced by aspartic proteases of Candida albicans is independent of proteolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.069